Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PRME vs VTYX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTYX Captures Overall Composite Edge (50.4 HOLD vs 52.2 HOLD), While PRME Leads 3–1 on Growth & Valuation Pillars

VTYX Overall Winner 6-Pillar Tally: PRME 3 – 1 VTYX (2 Tie) Matrix Metrics: PRME 2 – 5 VTYX

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Prime Medicine, Inc. (PRME) on higher Unified Composite conviction (50.4/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while PRME wins 3–1 across the 6-pillar growth and valuation breakdown. PRME trades at $4.24 (N/M Forward P/E, -4824.9% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While PRME currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4824.9% operating margin) and revenue trajectory (+0.0% vs. +3.5% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRME vs VTYX
PRME NASDAQ
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.24
-0.82% 1D
Market Cap $705.6M
TTM Revenue $4.1M
Forward P/E N/M
Beta / 30D Vol 2.44β · 149% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.8% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $4.32 · SMA50: $3.71
VTYX NASDAQ Head-to-Head Winner
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72

6-Pillar Scorecard Institutional Category Breakdown (PRME 3 – 1 VTYX)

Columns: Metric · PRME · VTYX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PRME
Revenue Growth (YoY) +3.5% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.1M N/A
Market Cap $705.6M $1.0B
3. Profitability & Quality VTYX
Gross Margin N/A N/A
Operating Margin -4824.9% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -373.3% -45.4%
4. Balance Sheet & Cash Flow PRME
Cash Generation (TTM) -$157M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $65M Net Debt (0.06x D/E) $2.68 Book/Sh · -45.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRME
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 139.6% (20th %ile) 0.5% (<1st %ile)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRME (2) vs VTYX (5)
Institutional Metric PRME VTYX Criterion Row Edge
Market Capitalization
Scale
$705.6M $1.0B Larger Scale VTYX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+3.5% +0.0% Higher Growth PRME
Operating Margin (TTM)
Profitability
-4824.9% 0.0% Higher Margin VTYX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-373.3% -45.4% Higher ROE VTYX
52-Week Range Position
Momentum
48% ($3–$6) 55% ($1–$25) Stronger Trend VTYX
Beta / 30D Volatility
Risk Regime
2.44β · 149% Vol 2.07β · 2% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite PRME
Trailing 12M Revenue (USD)
Operating Scale
$4.1M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$157M ($65M Net Debt (0.06x D/E)) N/A ($2.68 Book/Sh · -45.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRME +10.66 pp
PRME: +11.02% · VTYX: +0.36%
3M Horizon VTYX +29.27 pp
PRME: +10.73% · VTYX: +40.0%
6M Horizon VTYX +19.57 pp
PRME: +27.03% · VTYX: +46.6%
1Y Horizon VTYX +19.57 pp
PRME: +27.03% · VTYX: +46.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRME vs VTYX. Trailing 12-month operating profitability (PRME -4824.9% vs VTYX 0.0%) and valuation multiples (PRME N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PRME ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.1M
Gross MarginN/A
Op. Margin-4824.9%
ROE / Fwd P/E-373.3% · N/M
VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRME SURGE
13d in phase · OBV ACCUMULATION
Current IV 139.6%
IV Percentile 20th %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRME Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $705.6M market capitalization and -4824.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRME vs VTYX Key Questions & Quantitative Answers

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Prime Medicine, Inc. (PRME) on higher Unified Composite conviction (50.4/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while PRME wins 3–1 across the 6-pillar growth and valuation breakdown. PRME trades at $4.24 (N/M Forward P/E, -4824.9% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PRME currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4824.9% operating margin) and revenue trajectory (+0.0% vs. +3.5% YoY).

PRME leads the Growth & Scale pillar: PRME posts +3.5% YoY revenue growth and +0.0% YoY earnings growth on $4.1M TTM revenue (N/A gross margin, -4824.9% operating margin), compared with VTYX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRME generates $4.1M in USD-normalized revenue versus N/A for VTYX. In operating R&D and SG&A reinvestment, PRME deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTYX.

PRME and VTYX trade at balanced relative valuation multiples. PRME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRME (-373.3% ROE) versus VTYX (-45.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PRME carries 139.6% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (2.44β · 149% Vol realized risk). By comparison, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.